Immune Pharmaceuticals enrolls patients in trial for CMML drug
Immune Pharmaceuticals is enrolling patients in a Phase I and II clinical trial that will determine the safety and efficacy levels of Ceplene as a treatment for Chronic Myelomonocytic Leukemia. Read More »